刘春花;王明金;杨淑婷;黎娜;陆苑;潘洁;李勇军;王永林;孙佳;
LIU Chun-hua;WANG Ming-jin;YANG Shu-ting;LI Na;LU Yuan;PAN Jie;LI Yong-jun;WANG Yong-lin;SUN Jia;State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and Traditional Chinese Medicine (Ministry of Education), Guizhou Medical University;Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University;School of Pharmacy, Guizhou Medical University;

• 1:贵州医科大学省部共建药用植物功效与利用国家重点实验室/民族药与中药开发应用教育部工程研究中心
• 2:贵州医科大学贵州省药物制剂重点实验室
• 3:贵州医科大学药学院

摘要(Abstract)：

采用大鼠外翻肠囊模型考察荭草提取物在正常和心肌缺血模型大鼠的肠吸收特征。收集荭草提取物(5.0,10.0,20.0 mg·mL^(-1))在各肠段中的肠囊液,采用UPLC-TQD测定肠囊液中荭草素、异荭草素、牡荆素、原儿茶酸、山柰素-3-O-β-D-葡萄糖苷、槲皮苷6个化学成分的含量,计算吸收速率和累积吸收量,同时考察P-糖蛋白(P-gp)抑制剂对6种成分肠吸收的影响。结果发现,正常状态下,低、中、高浓度下,主要吸收部位分别是十二指肠、结肠和回肠;心肌缺血状态下,低浓度主要集中在回肠和空肠,中浓度在回肠,高浓度在十二指肠和回肠。与正常组相比,模型组中6种成分的吸收速率和累积吸收量均显著下降。P-gp抑制剂能显著提高模型组中6种成分的吸收速率和累积吸收量,推测荭草中的6种成分可能是P-gp的底物。外翻肠囊模型能有效评价荭草提取物中这6种成分在正常和心肌缺血状态下的肠吸收特征,该研究为荭草的临床用药和深入开发利用提供参考依据。
The present study is to investigate the absorption characteristics of the main components in Polygonum orientale extract in normal and isoproterenol-induced myocardial ischemia model rats with everted intestinal sac models. Intestinal sac fluid samples were collected in different part of intestine(duodenum, jejunum, ileum, colon) at different time after administration of different concentration of P. orientale extract(5.0,10.0, 20.0 mg·mL(-1))在各肠段中的肠囊液,采用UPLC-TQD测定肠囊液中荭草素、异荭草素、牡荆素、原儿茶酸、山柰素-3-O-β-D-葡萄糖苷、槲皮苷6个化学成分的含量,计算吸收速率和累积吸收量,同时考察P-糖蛋白(P-gp)抑制剂对6种成分肠吸收的影响。结果发现,正常状态下,低、中、高浓度下,主要吸收部位分别是十二指肠、结肠和回肠;心肌缺血状态下,低浓度主要集中在回肠和空肠,中浓度在回肠,高浓度在十二指肠和回肠。与正常组相比,模型组中6种成分的吸收速率和累积吸收量均显著下降。P-gp抑制剂能显著提高模型组中6种成分的吸收速率和累积吸收量,推测荭草中的6种成分可能是P-gp的底物。外翻肠囊模型能有效评价荭草提取物中这6种成分在正常和心肌缺血状态下的肠吸收特征,该研究为荭草的临床用药和深入开发利用提供参考依据。
The present study is to investigate the absorption characteristics of the main components in Polygonum orientale extract in normal and isoproterenol-induced myocardial ischemia model rats with everted intestinal sac models. Intestinal sac fluid samples were collected in different part of intestine(duodenum, jejunum, ileum, colon) at different time after administration of different concentration of P. orientale extract(5.0,10.0, 20.0 mg·mL^(-1)). An UPLC-TQD method was employed for the determination of six components including orientin, isoorientin, vitexin, protocatechuic acid, kaempferol-3-O-β-D-glucoside and quercitrin in the intestinal sac samples. The absorption rate and cumulative absorption were calculated to analyze the intestinal absorption characteristics of six components in normal and myocardial ischemia model rats. The P-glycoprotein(P-gp) inhibitor was applied to investigate influence of intestinal absorption of six components in P. orientale extract. The results showed that the main absorption sites were concentrated on the duodenum at low concentration, while they were the colon at the medium concentration and the ileum at high concentration in control groups. In the condition of myocardial ischemia model, the main absorption sites focus on the ileum and jejunum at low concentration; the main absorption sites were in the ileum at the medium concentration and main absorption sites were the duodenum and ileum at high concentration. Compared with the normal group, the absorption rate and cumulative absorption of the six components significantly decreased in the model group. P-gp inhibitor markedly increased the absorption rate and cumulative absorption of six components in the model group, inferring that the 6 components may be the substrates of P-gp, and the mechanism needs further study. In this study, it is revealed that the six components of P. orientale extract can be absorbed into the intestinal sac, and it is an effective method to assess the intestinal absorption characteristics of P. orientale extract through everted intestinal sac model, providing data support for the clinical application and further development of P. orientale.

关键词(KeyWords)： 荭草提取物;肠吸收;离体外翻肠囊法;心肌缺血;P-糖蛋白抑制剂
Polygonum orientale extract;intestinal absorption;everted intestinal sac model;myocardial ischemia;P-gp inhibitor

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81660712,81803700,U1812403);; 贵州省自然科学基金项目(黔科合基础[2020]1Z068);; 贵州省科学技术厅项目(黔科合平台人才[2016]5613/5677,黔科合平台人才[2017]5718);; 贵州省中医药管理局中医药、民族医药科学技术研究项目(QZYY-2018-108);; 中央引导地方科技专项(黔科中引地[2018]4006)

作者(Authors): 刘春花;王明金;杨淑婷;黎娜;陆苑;潘洁;李勇军;王永林;孙佳;
LIU Chun-hua;WANG Ming-jin;YANG Shu-ting;LI Na;LU Yuan;PAN Jie;LI Yong-jun;WANG Yong-lin;SUN Jia;State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and Traditional Chinese Medicine (Ministry of Education), Guizhou Medical University;Guizhou Provincial Key Laboratory of Pharmaceutics, Guizhou Medical University;School of Pharmacy, Guizhou Medical University;

DOI: 10.19540/j.cnki.cjcmm.20201010.201

参考文献(References)：

• [1] 巩仔鹏,陈颖,张瑞杰,等.疾病状态下的中药药代动力学研究进展[J].中国中药杂志,2015,40(2):169.
• [2] JOHN A,MANMEET S.Pathophysiology of coronary artery di-sease leading to acute coronary syndromes[J].F1000 Prime Rep,2015,7:8.
• [3] WANG Z,KLIPFELL E,BENNETT B J,et al.Gut flora meta-bolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57.
• [4] 侯灿,曹海涛.肠道菌群及其代谢产物与心血管疾病关系的研究进展[J].南京医科大学学报,2019,39(1):149.
• [5] 王燕,蔡军.肠道菌群与心血管疾病关系的研究进展[J].基础医学与临床,2017,37(5):729.
• [6] 王利娜,林晓,沈岚,等.临床常见疾病对中药药代动力学的影响[J].中国实验方剂学杂志,2015,21(18):206.
• [7] 王文祥,苏锦松,于猛,等.外翻肠囊法研究藏族药翼首草肠吸收成分及其吸收特征[J].中国中药杂志,2019,44(15):3170.
• [8] 祝诚诚,何新.药物肠道吸收研究方法[J].药物评价研究,2010,33(3):222.
• [9] 贵州省药品监督管理局.贵州省中药材、民族药材质量标准[S].贵阳:贵州科技出版社,2003.
• [10] 李勇军,何迅,刘丽娜,等.荭草化学成分的研究[J].中国中药杂志,2005,30(6):444.
• [11] 王爱民,王永林,刘丽娜,等.荭草药材的质量研究[J].中国中药杂志,2006,31(13):1047.
• [12] 黄勇,郑林,王爱民,等.荭草不同药用部位抗心肌缺血作用及化学成分比较研究[J].时珍国医国药,2010,21(10):2520.
• [13] 李月婷,李靖,肖婷婷,等.基于中药血清药物化学及血清药理学方法探讨荭草保护心肌细胞氧化损伤的物质基础[J].中国实验方剂学杂志,2013,19(2):158.
• [14] 周雯,李勇军,王爱民,等.荭草提取工艺研究[J].贵州医科大学学报,2007,32(2):206.
• [15] 李军.从复方荭草冻干粉针Ⅲ期平板运动试验结果谈活血化瘀治疗胸痹心痛[D].北京:中国中医科学院,2011.
• [16] 荣华,李大锋.复方荭草冻干粉针剂治疗冠心病心绞痛(心血瘀阻证)临床研究[J].湖北中医杂志,2008,30(3):14.
• [17] 王爱民,迟明艳,王永林,等.UPLC同时测定荭草药材中8种指标成分的含量[J].中国中药杂志,2010,35(13):1723.
• [18] QU C,XU D Q,YUE S J,et al.Pharmacodynamics and pharmacokinetics of Danshen in isoproterenol-induced acute myocar-dial ischemic injury combined with Honghua[J].J Ethnopharmacol,2020,247:112284.
• [19] 李晨辉,方伟,张敏,等.病理与生理状态下化痰降气胶囊大鼠血清移行成分对比研究[J].中国中药杂志,2020,45(6):1440.
• [20] SUN L,JIA H,LI J,et al.Cecal gut microbiota and metabolites might contribute to the severity of acute myocardial ischemia by impacting the intestinal permeability,oxidative stress,and energy metabolism[J].Front Microbiol,2019,10:1745.
• [21] 翁榕安,李小曼.药物小肠吸收的常用方法比较[J].医学综述,2009,15(2):269.
• [22] 李莹,陈思颖,巩仔鹏,等.离体外翻肠囊法研究红禾麻提取物在正常与类风湿性关节炎模型大鼠中的肠吸收特性差异[J].中国中药杂志,2020,45(2):405.
• [23] 朱竟赫,刘驰,刘禾,等.不同剂量异丙肾上腺素致小鼠慢性心肌缺血模型的制备及评价标准的建立[J].实验动物科学,2019,36(1):41.
• [24] LEI X L,DONG X F,LI L,et al.Powdered injections of luotai protect against ISO-induced experimental myocardial ischemia model on rats[J].Chin J Clin Pharmacol Ther,2000,5(2):147.
• [25] 陆苑,黎娜,刘春花,等.基于在体肠袢模型研究荭草活性成分在正常及心肌缺血模型大鼠的肠吸收特性[J].中国药理学通报,2020,36(8):1146.
• [26] 潘洁,杨淑婷,孙佳,等.荭草中6种活性成分在正常和心肌缺血模型大鼠体内的肠吸收特征差异研究[J].中国药房,2020,31(13):1562.
• [27] 吴林霖,李梅,巩仔鹏,等.基于大鼠离体外翻肠囊模型考察杜仲提取物在正常和自发性高血压状态下的肠吸收特性差异[J].中国实验方剂学杂志,2018,24(9):15.
• [28] 何帅,马晓杰,贺蕊,等.蜘蛛香35%乙醇提取物的肠吸收特性[J].中成药,2019,41(3):485.
• [29] ZHOU T,ARYA V,ZHANG L.Comparing various in vitro prediction methods to assess the potential of a drug to inhibit P-glycoprotein (P-gp) transporter in vivo[J].J Clin Pharmacol,2019,59(8):1049.